Company: | OvaScience, Inc. |
Ticker Symbol: | OVAS |
Class Period: | Feb-25-13 to Sep-10-13 |
Date Filed: | Jul-1-14 |
Lead Plaintiff Deadline: | Aug-30-14 |
Court: | District of Massachusetts |
Allegations: |
OvaScience is engaged in the discovery, development and commercialization of new treatments for infertility. The Company's product AUGMENT is an assisted reproductive technology which complements the existing standard of practice for an in vitro fertilization cycle.
The Complaint alleges that the Company misrepresented or failed to disclose material information concerning the clinical development of AUGMENT and regulatory concerns raised by the Food and Drug Administration that could potentially threaten or delay FDA approval of AUGMENT. On September 10, 2013, OvaScience disclosed that it was suspending enrollment of the AUGMENT clinical trial in the United States, after the Company received a letter from the FDA questioning whether AUGMENT qualified for reduced regulatory oversight and advising the Company to file an Investigational New Drug application.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.